Presbia Flexivue Microlens: Study Goal Met In Four Weeks

IRVINE, Calif.--(BUSINESS WIRE)--Presbia Holdings, through its subsidiary PresbiBio LLC, announced today that it completed treatment of subjects in the first stage of its pivotal U.S. FDA IDE study of the Presbia Flexivue Microlens™.

Participating in the study are Dr. Kerry Assil, Dr. Michael Caplan, Dr. Michael Gordon, Dr. Robert Maloney, Dr. Robert Rivera, and Dr. Karl Stonecipher. “This is an exciting time for Presbia, the four week rapid enrollment reinforces high consumer demand for a presbyopia solution and adds to our investigator’s armamentarium,” said Zohar Loshitzer, President of Presbia.

Help employers find you! Check out all the jobs and post your resume.